Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart.

[1]  F. Chen,et al.  Combination of VEGF(165)/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization. , 2007, European journal of pharmacology.

[2]  Zui Tan,et al.  Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs , 2007, Acta Pharmacologica Sinica.

[3]  Yijiang Chen,et al.  Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium , 2007, Scandinavian cardiovascular journal : SCJ.

[4]  L. Ye,et al.  Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF165 and angiopoietin‐1 , 2007, European journal of heart failure.

[5]  Y. Kan,et al.  AAV Serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect , 2006, Gene Therapy.

[6]  Yan-hong Guo,et al.  Augmentation of revascularization and prevention of plasma leakage by angiopoietin-1 and vascular endothelial growth factor co-transfection in rats with experimental limb ischaemia , 2006, Acta cardiologica.

[7]  H. Bøtker,et al.  NOGA-Guided Analysis of Regional Myocardial Perfusion Abnormalities Treated With Intramyocardial Injections of Plasmid Encoding Vascular Endothelial Growth Factor A-165 in Patients With Chronic Myocardial Ischemia: Subanalysis of the EUROINJECT-ONE Multicenter Double-Blind Randomized Study , 2005, Circulation.

[8]  T. Matsuyama,et al.  Angiopoietin 1 is mitogenic for cultured endothelial cells. , 2005, Cancer research.

[9]  D. McDonald,et al.  Long-Term and Sustained COMP-Ang1 Induces Long-Lasting Vascular Enlargement and Enhanced Blood Flow , 2005, Circulation research.

[10]  X. Gao,et al.  VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways , 2005, Gene Therapy.

[11]  Y. Kan,et al.  Adeno-Associated Viral Vector Delivered Cardiac-Specific and Hypoxia-Inducible VEGF Expression in the Ischemic Mouse Hearts , 2022 .

[12]  E. Foster,et al.  New technique for measurement of left ventricular pressure in conscious mice. , 2004, American journal of physiology. Heart and circulatory physiology.

[13]  H. Hamada,et al.  Pre‐administration of angiopoietin‐1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model , 2003, The journal of gene medicine.

[14]  M. Eskandarpour,et al.  Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. , 2003, Biochemical and biophysical research communications.

[15]  M. Weitzman,et al.  Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. , 2003, The Journal of thoracic and cardiovascular surgery.

[16]  L. V. von Segesser,et al.  Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: a comparative study with adenovirus vectors. , 2003, International journal of cardiology.

[17]  J. Isner,et al.  Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. , 2003, Life sciences.

[18]  L. Zentilin,et al.  Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[20]  Y. Kan,et al.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Chae,et al.  Coadministration of Angiopoietin-1 and Vascular Endothelial Growth Factor Enhances Collateral Vascularization , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[23]  R. Jain,et al.  Leaky vessels? Call Ang1! , 2000, Nature Medicine.

[24]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[25]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. , 1999, Current topics in microbiology and immunology.

[26]  P. Carmeliet,et al.  Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. , 1999, Current topics in microbiology and immunology.

[27]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[28]  B. Byrne,et al.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.